Cooperative Agreement NU01DD000007

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $286,510 Cooperative Agreement under the Blood Disorder Program: Prevention, Surveillance, and Research (CFDA 93.080) to the Center for Public Health Innovation, a woman-owned non-profit organization, for the Sickle Cell Data Collection Program - 2023. This 5-year project, beginning on September 30, 2023, aims to work with state health agencies and other partners to plan, develop, implement, coordinate, and evaluate programs and...

This federal Project Grant award of $254,604 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop and implement a collaborative care model to deliver a resilience-building intervention for adolescents and young adults (AYAs) with non-malignant blood disorders, such as sickle cell disease. The key activities include: Assessing the feasibility and acceptability of the "Promoting Resilience in Stress...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), aims to evaluate the use of accessory cells to improve homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will fund research to determine if co-infusing the CD34+ cells with the CD34-negative fraction, normally discarded after CD34+ cell...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $433,895.00 to the Sloan-Kettering Institute for Cancer Research to study the psychosocial, ethical, and clinical implications of incidentally identifying clonal hematopoiesis (CH) in healthy hematopoietic stem cell (HSC) donors. The key objectives of the two-year project are to: 1) qualitatively examine the psychosocial impact of receiving information...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $225,101 to investigate the mechanisms underlying the increased risk of hematological malignancy in sickle cell disease (SCD). The research will: Perform gain and loss of function experiments to study the impact of oxidative stress-induced DNA damage on the development of clonal hematopoiesis and hematological malignancies in SCD mouse models compared to normal controls....

This $398,207 Project Grant award, provided by the National Cancer Institute under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to develop and test a multilevel intervention to improve interdisciplinary communication quality in low-resource pediatric oncology hospitals. The key products and services to be delivered include: Identifying the relationship between communication structure and quality in the care of children with cancer through a cross-sectional social...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will fund a 5-year, $599,339 randomized trial to evaluate the efficacy of a multidisciplinary group-based telehealth intervention called HORIZONS. The intervention aims to improve quality of life, psychological distress, symptom burden, coping, and self-efficacy in hematopoietic stem cell transplant (HCT) survivors living with chronic graft-versus-host disease...

This Project Grant awarded by the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $252,285 to support a 5-year training program at St. Jude Children's Research Hospital focused on basic and translational research in pediatric classical hematology. The program will support three postdoctoral fellows conducting hypothesis-driven research to elucidate the mechanisms of non-malignant blood disorders and uncover new...

This $764,817 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to determine the mechanisms of bleeding associated with acute promyelocytic leukemia (APL). The research will utilize mouse models to evaluate the roles of specific pathways, including the podoplanin-CLEC-2 pathway, S100/annexin A2/tissue plasminogen activator (tPA) pathway, and urokinase-type plasminogen activator...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,410,766 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Florida to conduct a mixed methods comparative effectiveness analysis evaluating the implementation and impact of telehealth and home blood pressure monitoring strategies on blood pressure control during the COVID-19 pandemic. The key objectives of the five-year project are to: 1) evaluate trends and disparities in the utilization of...